# Effectiveness of Higher Aspirin Dosing for Prevention of Preeclampsia in High Risk Obese Gravida

Study · id `cardio:ct-nct03961360` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03961360](<https://clinicaltrials.gov/study/NCT03961360>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03961360

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 220 participants.

## Technical summary

Registry record NCT03961360. Randomized; no masking; primary purpose treatment. Start 2019-05-06 (actual); primary completion 2023-04-10 (actual). Results posted on 2024-05-08.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 220 participants (enrolled count; ClinicalTrials.gov record NCT03961360, source copy `cardio:ctgov-nct03961360-2024-05-08`, retrieved 2026-10-26)
- Started: 2019-05-06 (actual) (ClinicalTrials.gov record NCT03961360, source copy `cardio:ctgov-nct03961360-2024-05-08`, retrieved 2026-10-26)
- Primary completion: 2023-04-10 (actual) (ClinicalTrials.gov record NCT03961360, source copy `cardio:ctgov-nct03961360-2024-05-08`, retrieved 2026-10-26)
- Completion: 2023-04-10 (actual) (ClinicalTrials.gov record NCT03961360, source copy `cardio:ctgov-nct03961360-2024-05-08`, retrieved 2026-10-26)
- Results first posted: 2024-05-08 (ClinicalTrials.gov record NCT03961360, source copy `cardio:ctgov-nct03961360-2024-05-08`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT03961360, source copy `cardio:ctgov-nct03961360-2024-05-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03961360-2024-05-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effectiveness of Higher Aspirin Dosing for Prevention of Preeclampsia in High Risk Obese Gravida
- Acronym: ASPREO
- Condition: Pre-Eclampsia
- Condition: Hypertension in Pregnancy
- Condition: Obesity
- Intervention (Drug): Aspirin 81 mg
- Intervention (Drug): Aspirin 162 mg
- Lead sponsor: The University of Texas Health Science Center, Houston
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Aspirin (`core:aspirin`)
- Registry lists this organization as the lead sponsor: The University of Texas Health Science Center, Houston (`cardio:org-the-university-of-texas-health-science-center-houston`)

## Provenance

Content hash: 92e0b7c5db16e0e14da2f51835acea417684faf945d2804ea8d4227f33ba3c20
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
